Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

Clinical Trials of New Anti-AIDS Drug Begin


United Press International (06/21/89)

Los Angeles--Clinical trials of AZDU--a drug researchers hope will attack HIV and be less toxic than AZT--are underway. The Food and Drug Administration recently gave Triton Biosciences Inc. of Alameda, Calif., approval to evaluate the drug's effectiveness in HIV-infected individuals. The drug maker is conducting studies in conjunction with UCLA researchers. In addition to the trials at UCLA's AIDS Clinical Research Center, the National Institute of Allergy and Infectious Diseases has started a first phase safety and tolerance tests. In animal studies, the new drug was less toxic than AZT. AZDU disrupts HIV replication in infected cells.


Copyright © 1989 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in June 21, 1989. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.